CoChat

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Double-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes?

Open access
on behalf of the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), Giuffrida, Fernando M. A., Bulcão, Caroline, Cobas, Roberta A., Negrato, Carlos Antonio, Gomes, Marilia B., Dib, Sergio Atala · 2016 · Diabetology & Metabolic Syndrome

Abstract

BACKGROUND: Double diabetes (DD) describes both individuals with obesity upon diagnosis of type 1 diabetes and those who have gained weight during follow-up, although cardiovascular risk factors (CVRF) are not well understood in this group. We aim to evaluate the frequency of DD in a real-world type 1 diabetes sample and the interaction of insulin treatment with CVRF. METHODS: Multicentre cross-sectional study of 2711 individuals with clinical diagnosis of type 1 diabetes from secondary diabetes centres in 20 Brazilian cities. RESULTS: Patients with diabetes duration <5 and ≥5 years had similar frequency of overweight (20.4 vs. 25 %) and obesity, (9.8 vs. 6.1 %), p 0.28 for trend. Insulin dose (U/kg/day) was lower in obese individuals compared to normal BMI, with mean (95 % CI) 0.72 (0.62-0.83) vs. 0.88 (0.84-0.92) U/kg/day for diabetes duration <5 years and 0.84 (0.77-0.92) vs. 0.99 (0.97-1.01) U/kg/day for duration ≥5 years. Obese individuals had lower HDL (47.5 vs. 54.4 mg/dL) and higher non-HDL-cholesterol (134.5 vs. 115.2 mg/dL) than lean ones only among those with more than 5 years of diabetes. CONCLUSIONS: Lower insulin doses in obese individuals point to a role of clinical heterogeneity in insulin deficiency rather than normal progression of type 1 diabetes. Early obesity in type 1 diabetes is associated to lower HDL-cholesterol and higher number of CVRF. These data suggest a broad landscape of pathophysiological phenomena in double diabetes, rather than simple progression of a homogeneous clinical entity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13098-016-0143-7

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of initial sample, excluded patients and final number of studied individuals
Fig. 1 Flowchart of initial sample, excluded patients and final number of studied individualsCC BY · PubMed Central
Fig. 2 Relative frequencies of normal, overweight, and obese individuals, according to diabetes duration
Fig. 2 Relative frequencies of normal, overweight, and obese individuals, according to diabetes durationCC BY · PubMed Central
Fig. 3 Estimated marginal means and 95 % CIs (according to BMI status) for insulin dose (a divided by diabetes duration; b divided by gender); total number of insulin applications (c divided by diabetes duration; d divided by gender); HbA1c (e divided by diabetes duration; f divided by gender). Significant differences (p < 0.05) are marked with asterisks
Fig. 3 Estimated marginal means and 95 % CIs (according to BMI status) for insulin dose (a divided by diabetes duration; b divided by gender); total number of insulin applications (c divided by diabetes duration; d divided by gender); HbA1c (e divided by diabetes duration; f divided by gender). Significant differences (p < 0.05) are marked with asterisksCC BY · PubMed Central
Fig. 4 Estimated marginal means and 95 % CIs (according to BMI status) for HDL-cholesterol (a divided by diabetes duration; b divided by gender); non-HDL-cholesterol (c divided by diabetes duration; d divided by gender); mean blood pressure (e divided by diabetes duration; f divided by gender). Significant differences (p < 0.05) are marked with asterisks
Fig. 4 Estimated marginal means and 95 % CIs (according to BMI status) for HDL-cholesterol (a divided by diabetes duration; b divided by gender); non-HDL-cholesterol (c divided by diabetes duration; d divided by gender); mean blood pressure (e divided by diabetes duration; f divided by gender). Significant differences (p < 0.05) are marked with asterisksCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 20

Metadata

Authors
on behalf of the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), Giuffrida, F. M. A., Bulcão, C., Cobas, R. A., Negrato, C. A., Gomes, M. B., & Dib, S. A.
Affiliations
  • Universidade do Estado da Bahia (BR)
  • Universidade do Estado do Rio de Janeiro (BR)
Corresponding author
Giuffrida, Fernando M. A.
Venue
Diabetology & Metabolic Syndrome
Published
2016-03-22
Volume
8
Issue
1
Pages
28-28
ISSN
1758-5996 (ISSN-L)
OpenAlex
W2262945283
Cited by
20
References
28
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 1
FWCI
3.02
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
  • Cardiovascular Research Foundation
  • Universidade Federal de Sergipe
  • Universidade Federal do Maranhão
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
double diabetes, type 1 diabetes, obesity, insulin therapy, insulin dose, cardiovascular risk factors, HDL cholesterol, non-HDL cholesterol, diabetes duration, clinical heterogeneity, insulin deficiency, overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Double-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes? https://app.cochat.ai/papers/10.1186/s13098-016-0143-7
The paper
on behalf of the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), Giuffrida, F. M. A., Bulcão, C., Cobas, R. A., Negrato, C. A., Gomes, M. B., & Dib, S. A. (2016). Double-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes? Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-016-0143-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.